List of Tables
Table 1. Global Influenza Vaccine Market Size Growth Rate by Type (US$ Million): 2021 VS 2027
Table 2. Major Manufacturers of Trivalent Influenza Vaccine
Table 3. Major Manufacturers of Quadrivalent Influenza Vaccine
Table 4. Global Influenza Vaccine Market Size Growth by Application (US$ Million): 2021 VS 2027
Table 5. Global Influenza Vaccine Market Size by Region (US$ Million): 2021 VS 2027
Table 6. Global Influenza Vaccine Sales by Region (2016-2021) & (M Doses)
Table 7. Global Influenza Vaccine Sales Forecast by Region (2022-2027) & (M Doses)
Table 8. Global Influenza Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 9. Global Influenza Vaccine Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 10. Global Influenza Vaccine Sales by Manufacturer (2016-2021) & (M Doses)
Table 11. Global Influenza Vaccine Sales Share by Manufacturer (2016-2021)
Table 12. Influenza Vaccine Revenue by Manufacturer (2016-2021) & (US$ Million)
Table 13. Influenza Vaccine Revenue Share by Manufacturer (2016-2021)
Table 14. Key Manufacturers Influenza Vaccine Price (2016-2021) & (USD/Doses)
Table 15. Ranking of Global Top Influenza Vaccine Manufacturers by Revenue (US$ Million) in 2020
Table 16. Global Influenza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 17. Global Influenza Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Influenza Vaccine as of 2020)
Table 18. Influenza Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Influenza Vaccine Product Type
Table 20. Date of International Manufacturers Enter into Influenza Vaccine Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. CSL Corporation Information
Table 23. CSL Description and Business Overview
Table 24. CSL Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2016-2021)
Table 25. CSL Influenza Vaccine Product
Table 26. CSL Influenza Vaccine Revenue (US$ Million) and Market Share by Product
Table 27. CSL Influenza Vaccine Revenue (US$ Million) and Market Share by Application
Table 28. CSL Influenza Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 29. CSL Influenza Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 30. CSL Recent Development
Table 31. GSK Corporation Information
Table 32. GSK Description and Business Overview
Table 33. GSK Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2016-2021)
Table 34. GSK Influenza Vaccine Product
Table 35. GSK Influenza Vaccine Revenue (US$ Million) and Market Share by Product
Table 36. GSK Influenza Vaccine Revenue (US$ Million) and Market Share by Application
Table 37. GSK Influenza Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 38. GSK Influenza Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 39. GSK Recent Development
Table 40. Sanofi Pasteur Corporation Information
Table 41. Sanofi Pasteur Description and Business Overview
Table 42. Sanofi Pasteur Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2016-2021)
Table 43. Sanofi Pasteur Influenza Vaccine Product
Table 44. Sanofi Pasteur Influenza Vaccine Revenue (US$ Million) and Market Share by Product
Table 45. Sanofi Pasteur Influenza Vaccine Revenue (US$ Million) and Market Share by Application
Table 46. Sanofi Pasteur Influenza Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 47. Sanofi Pasteur Influenza Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 48. Sanofi Pasteur Recent Development
Table 49. Mylan Corporation Information
Table 50. Mylan Description and Business Overview
Table 51. Mylan Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2016-2021)
Table 52. Mylan Influenza Vaccine Product
Table 53. Mylan Influenza Vaccine Revenue (US$ Million) and Market Share by Product
Table 54. Mylan Influenza Vaccine Revenue (US$ Million) and Market Share by Application
Table 55. Mylan Influenza Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 56. Mylan Influenza Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 57. Mylan Recent Development
Table 58. Hulan Bio Corporation Information
Table 59. Hulan Bio Description and Business Overview
Table 60. Hulan Bio Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2016-2021)
Table 61. Hulan Bio Influenza Vaccine Product
Table 62. Hulan Bio Influenza Vaccine Revenue (US$ Million) and Market Share by Product
Table 63. Hulan Bio Influenza Vaccine Revenue (US$ Million) and Market Share by Application
Table 64. Hulan Bio Influenza Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 65. Hulan Bio Influenza Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 66. Hulan Bio Recent Development
Table 67. AstraZeneca Corporation Information
Table 68. AstraZeneca Description and Business Overview
Table 69. AstraZeneca Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2016-2021)
Table 70. AstraZeneca Influenza Vaccine Product
Table 71. AstraZeneca Influenza Vaccine Revenue (US$ Million) and Market Share by Product
Table 72. AstraZeneca Influenza Vaccine Revenue (US$ Million) and Market Share by Application
Table 73. AstraZeneca Influenza Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 74. AstraZeneca Recent Development
Table 75. CCBIO Corporation Information
Table 76. CCBIO Description and Business Overview
Table 77. CCBIO Influenza Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2016-2021)
Table 78. CCBIO Influenza Vaccine Product
Table 79. CCBIO Influenza Vaccine Revenue (US$ Million) and Market Share by Product
Table 80. CCBIO Influenza Vaccine Revenue (US$ Million) and Market Share by Application
Table 81. CCBIO Influenza Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 82. CCBIO Recent Development
Table 83. Global Influenza Vaccine Sales by Type (2016-2021) & (M Doses)
Table 84. Global Influenza Vaccine Sales Forecast by Type (2022-2027) & (M Doses)
Table 85. Global Influenza Vaccine Revenue by Type (2016-2021) & (US$ Million)
Table 86. Global Influenza Vaccine Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 87. Global Influenza Vaccine Sales by Application (2016-2021) & (M Doses)
Table 88. Global Influenza Vaccine Sales Forecast by Application (2022-2027) & (M Doses)
Table 89. Global Influenza Vaccine Revenue by Application (2016-2021) & (US$ Million)
Table 90. Global Influenza Vaccine Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 91. North America Influenza Vaccine Sales by Country (2016-2021) & (M Doses)
Table 92. North America Influenza Vaccine Sales by Country (2022-2027) & (M Doses)
Table 93. North America Influenza Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 94. North America Influenza Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 95. North America Influenza Vaccine Sales by Type (2016-2021) & (M Doses)
Table 96. North America Influenza Vaccine Sales by Application (2016-2021) & (M Doses)
Table 97. Asia-Pacific Influenza Vaccine Sales by Region (2016-2021) & (M Doses)
Table 98. Asia-Pacific Influenza Vaccine Sales by Region (2022-2027) & (M Doses)
Table 99. Asia-Pacific Influenza Vaccine Revenue by Region (2016-2027) & (US$ Million)
Table 100. Asia-Pacific Influenza Vaccine Revenue by Region (2022-2027) & (US$ Million)
Table 101. Asia-Pacific Influenza Vaccine Sales by Type (2016-2021) & (M Doses)
Table 102. Asia-Pacific Influenza Vaccine Sales by Application (2016-2021) & (M Doses)
Table 103. Europe Influenza Vaccine Sales by Country (2016-2021) & (M Doses)
Table 104. Europe Influenza Vaccine Sales by Country (2022-2027) & (M Doses)
Table 105. Europe Influenza Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 106. Europe Influenza Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 107. Europe Influenza Vaccine Sales by Type (2016-2021) & (M Doses)
Table 108. Europe Influenza Vaccine Sales by Application (2016-2021) & (M Doses)
Table 109. Latin America Influenza Vaccine Sales by Country (2016-2021) & (M Doses)
Table 110. Latin America Influenza Vaccine Sales by Country (2022-2027) & (M Doses)
Table 111. Latin America Influenza Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 112. Latin America Influenza Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 113. Latin America Influenza Vaccine Sales by Type (2016-2021) & (M Doses)
Table 114. Latin America Influenza Vaccine Sales by Application (2016-2021) & (M Doses)
Table 115. Middle East and Africa Influenza Vaccine Sales by Country (2016-2021) & (M Doses)
Table 116. Middle East and Africa Influenza Vaccine Sales by Country (2022-2027) & (M Doses)
Table 117. Middle East and Africa Influenza Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 118. Middle East and Africa Influenza Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 119. Middle East and Africa Influenza Vaccine Sales by Type (2016-2021) & (M Doses)
Table 120. Middle East and Africa Influenza Vaccine Sales by Application (2016-2021) & (M Doses)
Table 121. Influenza Vaccine Key Raw Materials, Industry Status and Trend
Table 122. Influenza Vaccine Key Raw Materials and Upstream Suppliers
Table 123. Influenza Vaccine Clients Status and Trend
Table 124. Influenza Vaccine Typical Clients
Table 125. Influenza Vaccine Distributors
Table 126. Key Drivers: Impact Analysis (2022-2027)
Table 127. Influenza Vaccine Market Drivers
Table 128. Influenza Vaccine Market Opportunities
Table 129. Influenza Vaccine Market Challenges
Table 130. Influenza Vaccine Market Restraints
Table 131. Influenza Vaccine Porter’s Five Forces Analysis
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Influenza Vaccine Product Picture
Figure 2. Global Influenza Vaccine Sales Market Share by Type in 2021 & 2027
Figure 3. Trivalent Influenza Vaccine Product Picture
Figure 4. Quadrivalent Influenza Vaccine Product Picture
Figure 5. Global Influenza Vaccine Sales Market Share by Application in 2021 & 2027
Figure 6. For Children (6 months to 3 years) Examples
Figure 7. For Adults and Children over 3 years Examples
Figure 8. Influenza Vaccine Report Years Considered
Figure 9. Global Influenza Vaccine Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Influenza Vaccine Market Size 2016-2027 (US$ Million)
Figure 11. Global Influenza Vaccine Sales 2016-2027 (K Units)
Figure 12. Global Influenza Vaccine Market Size Market Share by Region: 2021 Versus 2027
Figure 13. Global Influenza Vaccine Sales Market Share Forecast by Region (2016-2027)
Figure 14. Global Influenza Vaccine Revenue Market Share by Region (2016-2027)
Figure 15. Global Influenza Vaccine Sales Share by Manufacturer in 2020
Figure 16. Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 17. Global Influenza Vaccine Sales Market Share Forecast by Type (2016-2027)
Figure 18. Global Influenza Vaccine Revenue Market Share Forecast by Type (2016-2027)
Figure 19. Influenza Vaccine Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Figure 20. Global Influenza Vaccine Sales Market Share Forecast by Application (2016-2027)
Figure 21. Global Influenza Vaccine Revenue Market Share Forecast by Application (2016-2027)
Figure 22. Influenza Vaccine Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Figure 23. North America Influenza Vaccine Revenue 2016-2027 (US$ Million)
Figure 24. North America Influenza Vaccine Sales Market Share by Type (2016-2021)
Figure 25. North America Influenza Vaccine Sales Market Share by Application (2016-2021)
Figure 26. Asia-Pacific Influenza Vaccine Revenue 2016-2027 (US$ Million)
Figure 27. Asia-Pacific Influenza Vaccine Sales Market Share by Region (2016-2027)
Figure 28. Asia-Pacific Influenza Vaccine Revenue Market Share by Region (2016-2027)
Figure 29. Asia-Pacific Influenza Vaccine Sales Market Share by Type (2016-2021)
Figure 30. Asia-Pacific Influenza Vaccine Sales Market Share by Application (2016-2021)
Figure 31. Europe Influenza Vaccine Revenue Growth Rate 2016-2027 (US$ Million)
Figure 32. Europe Influenza Vaccine Sales Market Share by Country (2016-2027)
Figure 33. Europe Influenza Vaccine Revenue Market Share by Country (2016-2027)
Figure 34. Europe Influenza Vaccine Sales Market Share by Type (2016-2021)
Figure 35. Europe Influenza Vaccine Sales Market Share by Application (2016-2021)
Figure 36. Latin America Influenza Vaccine Revenue Growth Rate 2016-2027 (US$ Million)
Figure 37. Latin America Influenza Vaccine Sales Market Share by Country (2016-2027)
Figure 38. Latin America Influenza Vaccine Revenue Market Share by Country (2016-2021)
Figure 39. Latin America Influenza Vaccine Sales Market Share by Type (2016-2021)
Figure 40. Latin America Influenza Vaccine Sales Market Share by Application (2016-2021)
Figure 41. Middle East and Africa Influenza Vaccine Revenue Growth Rate 2016-2027 (US$ Million)
Figure 42. Middle East and Africa Influenza Vaccine Sales Market Share by Country (2016-2027)
Figure 43. Middle East and Africa Influenza Vaccine Revenue Market Share by Country (2016-2027)
Figure 44. Middle East and Africa Influenza Vaccine Sales Market Share by Type (2016-2021)
Figure 45. Middle East and Africa Influenza Vaccine Sales Market Share by Application (2016-2021)
Figure 46. Influenza Vaccine Supply Chain (Upstream and Downstream Market)
Figure 47. Global Production Market Share of Influenza Vaccine Raw Materials by Region in 2020
Figure 48. Influenza Vaccine Distribution Channels
Figure 49. Global Influenza Vaccine Percentage 2016-2027: Indirect Sales VS Direct Sales
Figure 50. Global Influenza Vaccine Percentage 2016-2027: Online Sales VS Offline Sales
Figure 51. Porter's Five Forces Analysis
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed